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The reader will come to: 
 Appreciate that infection prevention measures in cystic fibrosis are based on theoretical 
benefit more than proven efficacy. 
 Understand that to be successful, infection control measures need to be simple, universally 
applied and acceptable. 
 
Future directions for research: 
 Provide evidence for or against simple measures such as masks, gowns and gloves as the 
centrepiece of infection prevention. 






As awareness of the risks of cross infection has increased, infection prevention and control 
measures have become more draconian. Infection control measures can have a profound effect of 
the organisation and delivery of CF services and on the lives of people with CF outside the 
hospital. However, the consequences of inadequate infection control measures may be the 
permanent acquisition of a chronic infection which is virtually untreatable. Recommendations for 
infection prevention and control therefore must protect patients but should also be evidence-based 
and proportionate. This article will review the literature, juxtaposing evidence and popular practice.    
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The last half century has seen a dramatic improvement in the life expectancy and quality of life for 
people with cystic fibrosis (CF).1 Much of the early improvement in these outcomes has been 
attributed to the frequent use of 14 day courses of intravenous antibiotics, particularly for those 
patients who have chronic pulmonary infection with Pseudomonas aeruginosa.2 Furthermore, long 
term antibiotic regimens are used in CF such as oral azithromycin and inhaled antibiotics (e.g. 
colistimethate sodium, tobramycin and aztreonam). Each of these approaches will contribute to 
the selection of resistant organisms in the CF airway. Patients with CF may therefore develop 
chronic pulmonary infection with multi-drug resistant organisms including: P. aeruginosa; 
methicillin resistant Staphylococcus aureus (MRSA); Burkholderia cepacia complex and non-
tuberculous mycobacteria, particularly Mycobacterium abscessus.3 
 
Since these infections were first described in CF, there has been concern that multi-drug resistant 
infection can be acquired by person to person spread between CF patients or from an 
environmental source (either in the CF centre or the home). Person to person spread has been 
proposed for multi-drug resistant P. aeruginosa,4 MRSA,5 B. cepacia complex6 and M. 
abscessus.7 Acquisition of both P. aeruginosa8 and MRSA5 from the hospital environment has 
been suggested. P. aeruginosa is present in the homes of CF patients with a new pulmonary 
infection but it has not been established whether the patient contaminates their environment or 
vice versa.9 Uncertainty about the risks of acquiring infection either from other patients or from the 
environment has given rise to pervasive anxiety in the CF community.10 In one survey, parents 
reported using a mean of 11 “hygienic measures” in the home, including ensuring their child had a 
different toothbrush for morning and evening and removing all pot plants from the house.11  
 
As awareness of the risks of cross infection has increased, infection prevention and control 
measures have become more draconian. Following reports of the transmission of Burkholderia 
cepacia complex by social contact, infection control guidelines were published advising against 
any social contact between people with CF and avoiding activities such as CF camps.12 The first 
edition of the US CF Foundation consensus document on infection control13 stated that: “No 
recommendation can be made for the routine wearing of masks by CF patients…” The most recent 
edition of the same guideline14 states that: “All people with CF, regardless of respiratory tract 
culture results, should wear a surgical…mask when in a healthcare setting…” Infection control 
measures can have a profound effect of the organisation and delivery of CF services and on the 
lives of people with CF outside the hospital. However, the consequences of inadequate infection 
control measures may be the permanent acquisition of a chronic infection which is virtually 
untreatable. Recommendations for infection prevention and control therefore must protect patients 
but should also be evidence-based and proportionate.  
 
So how robust is the evidence? That depends on how high we set the bar. Conventional clinical 
trials are designed to show a difference (improvement) in the group mean with an intervention. 
With cross infection, we are in pursuit of zero infection and so an improvement in the group mean 
may not be enough. A recent systematic review found only 2 randomised controlled trials of 
infection prevention and control measures in CF – the majority of studies being a “before and 
after” design.15  
 
 Segregation. When patients attend their CF centre, it is no longer proposed that they are 
cohorted together with other patients who have the same organism but rather individual 
segregation is recommended. These changes have been driven by the observation that an 
epidemic strain of P. aeruginosa can cross-infect patients with less pathogenic strains16 and 
by the unquantifiable risk of a new transmissible pathogen appearing within a cohort who 
are mixing freely. Only one study (before and after) has evaluated individual segregation of 
CF patients and this found no significant difference in acquisition of P. aeruginosa after 
segregation was introduced.17 A post hoc subgroup analysis of these data suggested that 
acquisition of P. aeruginosa was reduced in children.  
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 Hand hygiene is practiced universally in health care settings and is acceptable to patients 
and staff. One before and after study has examined the efficacy of hand hygiene in CF but 
did not demonstrate a reduced risk of transmission with hand hygiene measures.18  
 Gowns and gloves. A systematic review, looked at 23 studies of glove use in health 
workers and found that, although gloving can reduce acquisition of microorganisms on the 
hands, inappropriate glove use is frequent and can increase the risk of transmission of 
infection by health workers.19 An observational study on a medical ward and intensive care 
unit documented that frequently gloves were neither discarded nor hand hygiene performed 
after patient contact.20 A study in 4 US hospitals found that skin contamination of the health 
worker occurred during gown and glove removal in 46% of cases.21 Current CF infection 
control guidelines recommend that gowns and gloves are worn for all patient contact.14  
 Face masks. Perhaps one of the most contentious issues is the question of whether face 
masks should be worn by all CF patients when attending the CF centre. A randomised 
controlled trial of face mask use found that air contamination during CF clinic visits was 
infrequent and was not reduced by the use of masks.18 In contrast, studies of air 
contamination in CF adults using a “cough rig” have shown that face masks reduce the 
generation of P. aeruginosa aerosols22 and that the density of organisms is reduced for 
wear periods of up to 40 minutes.23   
 High-efficiency particulate air (HEPA) filters and air changes. Performing spirometry 
has been shown to increase room air contamination24 and it is recommended that a HEPA 
filter is used in the spirometry room (equivalent to 12 air changes per hour) or else 30 
minutes should elapse before the room is used by the next patient.14 However, differences 
in the number of air changes per hour have not been shown to affect air contamination.24  
 
None of these recommendations will be effective if they are not implemented consistently by 
patients and staff. A recent survey of paediatric CF centres in Ireland showed that only one centre 
adhered to the recommendation on gowns and gloves and no centres followed the 
recommendation on use of face masks or room ventillation.25 There is some evidence which 
suggests that infection control measures can compromise patient care.26  
 
So does infection prevention and control allow room for pragmatism? Hand hygiene and individual 
segregation should be practiced in every CF centre. However HEPA filtration may work best when 
it is part of the design of new-build CF facilities. In the meantime, many centres will have to opt for 
leaving spirometry rooms vacant and ventilated for 30 minutes after use. Glove use may add little 
to infection prevention through simple hand hygiene. Indeed gloves may give false reassurance 
and may lead to appropriate hand hygiene being omitted after patient contact. Face masks remain 
controversial and their efficacy in children has not yet been demonstrated. Some paediatric 
centres may await further evidence before deciding on the use of face masks. There is little 
evidence on how to reduce environmental acquisition in the home and CF centres should restrict 
their advice to measures which are evidence-based and readily implemented. Careful pragmatic 
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